Comprehensive genetic testing, including PRKAG2 mutation analysis, is crucial for differentiating PRKAG2 syndrome from sarcomeric HCM and other metabolic cardiomyopathies, ensuring appropriate risk stratification and early intervention. The gene discussed is PRKAG2; the disease is PRKAG2-related cardiomyopathy.